Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 19

1.

Ranibizumab and bevacizumab for neovascular age-related macular degeneration.

CATT Research Group, Martin DF, Maguire MG, Ying GS, Grunwald JE, Fine SL, Jaffe GJ.

N Engl J Med. 2011 May 19;364(20):1897-908. doi: 10.1056/NEJMoa1102673. Epub 2011 Apr 28.

2.

Ranibizumab: a review of its use in the treatment of neovascular age-related macular degeneration.

Frampton JE.

Drugs Aging. 2013 May;30(5):331-58. doi: 10.1007/s40266-013-0077-9. Review.

PMID:
23539234
3.

Ranibizumab and pegaptanib for the treatment of age-related macular degeneration: a systematic review and economic evaluation.

Colquitt JL, Jones J, Tan SC, Takeda A, Clegg AJ, Price A.

Health Technol Assess. 2008 May;12(16):iii-iv, ix-201. Review.

4.

Ranibizumab for age-related macular degeneration: a meta-analysis of dose effects and comparison with no anti-VEGF treatment and bevacizumab.

Jiang S, Park C, Barner JC.

J Clin Pharm Ther. 2014 Jun;39(3):234-9. doi: 10.1111/jcpt.12146. Epub 2014 Mar 17. Review.

PMID:
24635444
5.

Ranibizumab for the treatment of neovascular age-related macular degeneration: a review.

Kourlas H, Abrams P.

Clin Ther. 2007 Sep;29(9):1850-61. Review.

PMID:
18035187
6.
7.

Ranibizumab: Phase III clinical trial results.

Rosenfeld PJ, Rich RM, Lalwani GA.

Ophthalmol Clin North Am. 2006 Sep;19(3):361-72. Review.

PMID:
16935211
8.

Bevacizumab and neovascular age related macular degeneration: pathogenesis and treatment.

El-Mollayess GM, Noureddine BN, Bashshur ZF.

Semin Ophthalmol. 2011 May;26(3):69-76. doi: 10.3109/08820538.2010.545100. Review.

PMID:
21609219
9.

Ranibizumab in neovascular age-related macular degeneration.

Kenneth TE, Kertes PJ.

Clin Interv Aging. 2006;1(4):451-66. Review.

10.

A systematic review on the effect of bevacizumab in exudative age-related macular degeneration.

Schouten JS, La Heij EC, Webers CA, Lundqvist IJ, Hendrikse F.

Graefes Arch Clin Exp Ophthalmol. 2009 Jan;247(1):1-11. doi: 10.1007/s00417-008-0952-y. Epub 2008 Oct 9. Review.

PMID:
18843500
11.

Ranibizumab versus bevacizumab for the treatment of neovascular age-related macular degeneration.

Abouammoh M, Sharma S.

Curr Opin Ophthalmol. 2011 May;22(3):152-8. doi: 10.1097/ICU.0b013e32834595d0. Review.

PMID:
21483262
12.

A systematic review of as needed versus treat and extend ranibizumab or bevacizumab treatment regimens for neovascular age-related macular degeneration.

Chin-Yee D, Eck T, Fowler S, Hardi A, Apte RS.

Br J Ophthalmol. 2016 Jul;100(7):914-917. doi: 10.1136/bjophthalmol-2015-306987. Epub 2015 Oct 29. Review.

PMID:
26516125
13.

Off-label use of bevacizumab for the treatment of age-related macular degeneration: what is the evidence?

Ziemssen F, Grisanti S, Bartz-Schmidt KU, Spitzer MS.

Drugs Aging. 2009;26(4):295-320. doi: 10.2165/00002512-200926040-00002. Review.

PMID:
19476398
14.

Preclinical aspects of anti-VEGF agents for the treatment of wet AMD: ranibizumab and bevacizumab.

Meyer CH, Holz FG.

Eye (Lond). 2011 Jun;25(6):661-72. doi: 10.1038/eye.2011.66. Epub 2011 Apr 1. Review.

15.

Ranibizumab.

Blick SK, Keating GM, Wagstaff AJ.

Drugs. 2007;67(8):1199-206; discussion 1207-9. Review.

PMID:
17521219
16.

A safety review and meta-analyses of bevacizumab and ranibizumab: off-label versus goldstandard.

Schmucker C, Ehlken C, Agostini HT, Antes G, Ruecker G, Lelgemann M, Loke YK.

PLoS One. 2012;7(8):e42701. doi: 10.1371/journal.pone.0042701. Epub 2012 Aug 3. Review.

17.

Ranibizumab versus bevacizumab for ophthalmic diseases related to neovascularisation: a meta-analysis of randomised controlled trials.

Wu B, Wu H, Liu X, Lin H, Li J.

PLoS One. 2014 Jul 1;9(7):e101253. doi: 10.1371/journal.pone.0101253. eCollection 2014. Review.

18.

[Off-label prescribing: scientific analysis taking the use of bevacizumab in ophthalmology as an example].

Alarc√£o J, Costa J, Fareleira F, Borges M, Carneiro AV.

Acta Med Port. 2013 Jul-Aug;26(4):409-19. Epub 2013 Aug 30. Review. Portuguese.

19.

Ranibizumab in Treating Age-Related Macular Degeneration [Internet].

Swedish Council on Health Technology Assessment.

Stockholm: Swedish Council on Health Technology Assessment (SBU); 2008 May 21.

Supplemental Content

Support Center